Verition Fund Management LLC Takes $995,000 Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Verition Fund Management LLC purchased a new stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 199,729 shares of the company's stock, valued at approximately $995,000. Verition Fund Management LLC owned 0.22% of Aquestive Therapeutics as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in AQST. Vanguard Group Inc. raised its stake in shares of Aquestive Therapeutics by 71.7% in the first quarter. Vanguard Group Inc. now owns 3,242,571 shares of the company's stock valued at $13,813,000 after purchasing an additional 1,353,518 shares in the last quarter. Bank of New York Mellon Corp bought a new stake in Aquestive Therapeutics in the 2nd quarter valued at $594,000. Financial Advocates Investment Management raised its stake in shares of Aquestive Therapeutics by 70.0% in the 2nd quarter. Financial Advocates Investment Management now owns 34,000 shares of the company's stock valued at $88,000 after buying an additional 14,000 shares in the last quarter. Rhumbline Advisers bought a new position in shares of Aquestive Therapeutics during the 2nd quarter worth about $254,000. Finally, Victory Capital Management Inc. acquired a new stake in shares of Aquestive Therapeutics during the 2nd quarter valued at about $27,000. Institutional investors and hedge funds own 32.45% of the company's stock.

Aquestive Therapeutics Trading Down 6.7 %

NASDAQ AQST traded down $0.28 during trading hours on Monday, reaching $3.89. 2,338,375 shares of the company's stock were exchanged, compared to its average volume of 1,742,594. The firm has a fifty day moving average of $4.92 and a 200-day moving average of $4.04. Aquestive Therapeutics, Inc. has a one year low of $1.84 and a one year high of $6.23. The stock has a market cap of $354.69 million, a PE ratio of -8.64 and a beta of 2.63.

Remove Ads

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its earnings results on Monday, November 4th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.01). The firm had revenue of $13.54 million during the quarter, compared to the consensus estimate of $12.69 million. During the same period in the previous year, the business posted ($0.03) EPS. As a group, research analysts forecast that Aquestive Therapeutics, Inc. will post -0.47 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have commented on AQST shares. HC Wainwright restated a "buy" rating and set a $10.00 price target on shares of Aquestive Therapeutics in a research note on Wednesday, November 6th. Leerink Partners boosted their price target on Aquestive Therapeutics from $12.00 to $13.00 and gave the company an "outperform" rating in a research note on Friday, October 25th. Finally, JMP Securities reiterated a "market outperform" rating and issued a $9.00 price target on shares of Aquestive Therapeutics in a research report on Tuesday, October 8th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Aquestive Therapeutics has an average rating of "Buy" and an average price target of $9.80.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.